Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 19/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 18/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 17/20 | 1.00 |
| ▸ | CDK4 | P11802 | 11/20 | 0.67 |
| ▸ | CCND1 | P24385 | 10/20 | 0.67 |
| ▸ | CDK1 | P06493 | 9/20 | 0.67 |
| ▸ | CCNB2 | O95067 | 8/20 | 0.67 |
| ▸ | CCNB1 | P14635 | 8/20 | 0.67 |
| ▸ | CCNB3 | Q8WWL7 | 8/20 | 0.67 |
| ▸ | CCND2 | P30279 | 1/20 | 0.60 |
| ▸ | CCND3 | P30281 | 1/20 | 0.60 |
| ▸ | CDK7 | P50613 | 1/20 | 0.52 |
| ▸ | CDK9 | P50750 | 1/20 | 0.52 |
| ▸ | ITK | Q08881 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213819 | 0.80 | CCNE2 (1.00) | CDK2CCNE1CCNE2CDK4CCND1 | |
| SCHEMBL4991701 | 0.78 | CCNE1 (1.00) | CDK2CCNE1CCNE2CDK4CCND1 | |
| SCHEMBL16731888 | 0.77 | CCNE1 (0.68) | CDK2CCNE1CCNE2CDK4CCND1 | |
| SCHEMBL6695938 | 0.76 | CCNE2 (0.76) | CDK2CCNE1CCNE2CDK4CCND1 | |
| SCHEMBL14040956 | 0.76 | CCNE2 (0.83) | CDK2CCNE1CCNE2CDK4CCND1 | |
| SCHEMBL4734684 | 0.75 | CCNE2 (1.00) | CDK2CCNE1CCNE2CDK4CCND1 | |
| SCHEMBL5213493 | 0.74 | CCNE2 (0.80) | CDK2CCNE1CCNE2CDK4CCND1 | |
| SCHEMBL7514412 | 0.73 | CCNE1 (0.89) | CDK2CCNE1CCNE2CDK4CCND1 | |
| SCHEMBL2666164 | 0.72 | CCNE1 (0.69) | CDK2CCNE1CCNE2CDK4CCND1 | |
| SCHEMBL9096131 | 0.70 | CCNE1 (0.61) | CDK2CCNE1CCNE2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188524-A1 | Methods of treating pain | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-08-07 | — | — | US | claimed |
| WO-2008049856-A2 | METHODS OF TREATING PAIN USING CDK INHIBITORS | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-05-02 | — | — | WO | claimed |
| EP-1042307-B1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2007-10-03 | — | — | EP | claimed |
| EP-1042307-A4 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2003-01-29 | — | — | EP | claimed |
| US-20020137778-A1 | Aminothiazole inhibitors of cyclin dependent kinases | KIM KYOUNG S (US) | 2002-09-26 | — | — | US | claimed |
| EP-1240153-A1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | Bristol-Myers Squibb Company (US) | 2002-09-18 | — | — | EP | claimed |
| WO-2001044217-A1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | claimed |
| EP-1042307-A1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-10-11 | — | — | EP | claimed |
| US-6040321-A | ENZYME INHIBITOR TREATING CANCER, INFLAMMATION AND ARTHRITIS, NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE, CARDIOVASCULAR DISEASES, VIRAL DISEASES AND FUNGAL DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-21 | — | — | US | claimed |
| WO-1999024416-A1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-05-20 | — | — | WO | claimed |
| US-20080188524-A1 | Methods of treating pain | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-08-07 | — | — | US | disclosed |
| WO-2008049856-A2 | METHODS OF TREATING PAIN USING CDK INHIBITORS | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-05-02 | — | — | WO | disclosed |
| EP-1042307-B1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2007-10-03 | — | — | EP | disclosed |
| US-6521759-B2 | Anticancer, antiarthritic, and antiinflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-18 | — | — | US | disclosed |
| EP-1042307-A4 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2003-01-29 | — | — | EP | disclosed |
| US-6262096-B1 | IN COMBINATION WITH A MODULATOR OF P53 TRANSACTIVATION FORMULATED AS A FIXED DOSE. | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-17 | — | — | US | disclosed |
| WO-2001044217-A1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | disclosed |
| EP-1042307-A1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-10-11 | — | — | EP | disclosed |
| US-6040321-A | ENZYME INHIBITOR TREATING CANCER, INFLAMMATION AND ARTHRITIS, NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE, CARDIOVASCULAR DISEASES, VIRAL DISEASES AND FUNGAL DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-21 | — | — | US | disclosed |
| WO-1999024416-A1 | AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188524-A1 | Methods of treating pain | CDK3, CDK1, CDK5 | CDK2 4/4885CCNE1 137/4885CCNE2 84/4885 |
| US-20020137778-A1 | Aminothiazole inhibitors of cyclin dependent kinases | CCNI, CDK1, CCNK | CDK2 6/4885CCNE1 5/4885CCNE2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.